Susan Ratay, DO
Family Medicine · Ashtabula, OHNPI 1720333222
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $325,580 of the $378,615 with a category attached, or 86.0%. 52 manufacturers reported payments, led by AstraZeneca at 55.0% of the total. 2025 is the largest year on record at $164,834, more than ten times the $2,902 reported in 2019. Among family medicine clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,015 payments — averaging $373.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$208K
- Novo Nordisk$161K
- AbbVie$3K
- Lilly USA, LLC$772
- Pfizer$727
- Bayer$535
- plus $4K from 46 others
What the payments were for
- Consulting fees$24,2256%
- Speaking & faculty fees$325,58086%
- Travel & lodging$7,8832%
- Food & beverage$20,4795%
- Education$4480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$378,615 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 170 | $304,335 |
| MounjaroTirzepatide | 181 | $234,731 |
| EliquisApixaban | 89 | $106,238 |
| FarxigaDapagliflozin Propanediol | 88 | $96,262 |
| JardianceEmpagliflozin | 54 | $87,181 |
| TrulicityDulaglutide | 35 | $49,229 |
| JanuviaSitagliptin Phosphate | 39 | $34,188 |
| MyrbetriqMirabegron | 22 | $31,202 |
| Repatha SureclickEvolocumab | 33 | $31,153 |
| WegovySemaglutide | 16 | $22,980 |
| ProliaDenosumab | 12 | $20,505 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $20,381 |
| XareltoRivaroxaban | 17 | $17,499 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $12,098 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $7,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $161,286 | $327,315186 claims |
| Lilly USA, LLCMounjaro, Trulicity | $772 | $283,960216 claims |
| PfizerEliquis, Paxlovid | $727 | $107,668111 claims |
| AstraZenecaFarxiga | $208,414 | $96,26288 claims |
| Boehringer IngelheimJardiance | $260 | $87,18154 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $188 | $38,03549 claims |
| MerckJanuvia | $98 | $34,18839 claims |
| Astellas Pharma US IncMyrbetriq | $145 | $31,20222 claims |
| AmgenProlia | $344 | $20,50512 claims |
| Johnson & JohnsonXarelto | $40 | $17,49917 claims |
| AbbVieSynthroid | $3,085 | $1,66485 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Ashtabula
- Kwabena OtengSpringdale$2M
- Brian BeesleyColumbus$1.4M
- Darshana PatelBeachwood$648K
- Thomas GraceFindlay$503K
- Shannon TrotterSpringfield$348K
- Michael HeileCincinnati$272K
- Bradley EverlyMaumee$266K
- Tricia BedrickCuyahoga Falls$259K
- David NeidhardtLima$248K
- Paul HanahanPainesville$241K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.